2026– date –
-
NIH Launches ‘TRDNT Challenge’ to Drive Development of Precision RNA-Targeting Therapeutics for Disease
NIH USA Overview The National Institutes of Health (NIH) has initiated Phase I of the 'Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge' to foster a new class of RNA-targeting technologies. This initiative aims to accel... -
Ribocure, a Suzhou Ribo Life Science Subsidiary, Reports 92% FXI Activity Reduction in Phase IIa Vortosiran Trial for Coronary Artery Disease
Clinical Trials Arena UK Overview Ribocure Pharmaceuticals, a subsidiary of Suzhou Ribo Life Science, announced promising initial results from its Phase IIa clinical trial of vortosiran (RBD4059), an siRNA therapy for coronary artery dis... -
Model-Optimized Bispecific Antibodies: A Novel Strategy to Enhance ADC Tumor Selectivity
Academia.edu USA Overview Research from Academia.edu elucidates the potential of computationally optimized bispecific antibodies (BsAbs) to enhance the tumor selectivity of Antibody-Drug Conjugates (ADCs). As ADC efficacy remains constra... -
Antibody-Drug Conjugates Evolve from ‘Magic Bullet’ to Standard of Care in Solid Tumors, T-DXd and Combination Therapies Set New Benchmarks
Binaytara USA Overview Antibody-Drug Conjugates (ADCs) have significantly evolved in solid tumor treatment, transitioning from a 'magic bullet' concept to a 'standard of care.' Globally, over 12 ADCs are approved, with more than 300 in c... -
Frontiers Review Highlights RNA-Based Drugs’ Transformative Role in Modern Medicine, Emphasizing siRNA, mRNA, and ASO Delivery Strategies
Frontiers Switzerland Overview A Frontiers review comprehensively outlines the evolution of RNA therapeutics into innovative medical approaches by directly targeting disease-related RNA molecules. The review highlights the mechanisms of ... -
Tango Therapeutics Unveils TNG961, First Selective Oral HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers, a New Precision Oncology Strategy
AACR Journals (Cancer Discovery) USA Overview Tango Therapeutics announced the development of TNG961, the first selective oral HBS1L molecular glue degrader targeting FOCAD-deleted cancers. TNG961 induces translational arrest by disrupti... -
Hongene Biotech: Scaling Oligonucleotide Manufacturing Crucial for Surging siRNA Demand in Cardiometabolic Diseases
Hongene Biotech China Overview Hongene Biotech emphasizes the critical need for a dramatic scale-up in oligonucleotide manufacturing to meet the surging demand for siRNA therapeutics targeting cardiometabolic diseases. Driven by the succ... -
siRNA Overcomes Gene Silencing Challenges with LNP and GalNAc Conjugation, Expanding Therapeutic Applications
Inside Therapeutics USA Overview Inside Therapeutics details how siRNA, while offering transformative gene silencing, is overcoming delivery challenges through lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) conjugation tech... -
Investor Focus: RNA Platform Success Hinges on Extrahepatic Delivery Capabilities Beyond the Liver
Bioprocess Online USA Overview Bioprocess Online highlights that a key question for investors evaluating RNA therapeutic platforms is the ability to effectively deliver RNA to diverse extrahepatic organs. While current successes often le... -
Patient-Specific Lymphoid Organ Chips Recapitulate mRNA Vaccine Immune Response, Accelerating Preclinical Evaluation
Wyss Institute USA Overview Researchers at the Wyss Institute have developed an innovative technology capable of replicating mRNA vaccine-induced immune responses on patient-specific Lymphoid Organ Chips. This human-derived, ex vivo mode...
